RMD logo

ResMed

RMD · What the business does, what can go wrong, and how options sellers approach it

What it does

ResMed makes devices and software for people with sleep apnea and other breathing disorders. Its main products are flow generators (the machines that deliver pressurized air, often called CPAP devices), masks, and accessories such as tubing and headgear. It also sells software that helps patients, clinicians and care providers track therapy and manage patients outside the hospital.

How it makes money

Sales come from a few main streams. The first is devices, which are bought when a patient starts therapy or replaces an older machine. The second is masks and accessories, which wear out and are replaced regularly, so they tend to bring in recurring revenue from the installed base of patients. Software and digital health tools add a smaller third piece. Customers are mostly home medical equipment providers, distributors and healthcare systems, and payers such as insurers and government programs often decide what gets reimbursed.

Why investors own it

  • Sleep apnea is widely considered underdiagnosed, so more screening could expand the patient pool.
  • Ageing populations and rising obesity rates are often cited as long-term demand drivers.
  • Recurring mask and accessory replacement can make revenue steadier than a pure device business.
  • Therapy data and digital tools may help the company stand out and keep patients using treatment.

What can go wrong

  • Competition from other device makers, or from new treatment approaches such as medications or implants, could reduce demand for CPAP therapy.
  • Changes in reimbursement or healthcare policy can squeeze pricing.
  • Product recalls or safety issues can hurt trust and sales.
  • Supply chain disruptions and currency swings can affect results, since the company sells globally.
  • Regulatory scrutiny of medical devices and patient data is ongoing.

What to watch

  • Device and mask unit growth
  • Gross margin trends
  • New-patient starts and resupply rates
  • Reimbursement and policy changes
  • Competitor product launches and treatment alternatives
  • Growth in digital health and software offerings
  • Regulatory announcements and recalls

Options income angle

Options on RMD are generally available across multiple expirations, though they are typically less active than those on the largest mega-cap names. Spreads can be wider on far-dated or far-from-the-money strikes, so liquidity is worth checking before trading.

Implied volatility tends to rise ahead of quarterly earnings and around news on competing therapies or reimbursement. It often falls after those events pass.

One caution for premium sellers: a sharp gap move on earnings or on competitive news can quickly overwhelm the premium collected, so position size and the risk of assignment deserve careful thought.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended June 30, 2026, filed August 13, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

ResMed grew revenue and profit in the year ended June 30, 2026, led by its sleep and breathing devices and masks. The company is reshaping its portfolio, buying Noctrix and agreeing to sell MatrixCare, which adds new regulatory exposure and execution risk. The filing also flags competition from sleep apnea drugs and a recovering Philips, reliance on single-source suppliers, and tax changes.

How the business did

  • Net revenue rose to $5,653 million from $5,146 million, an increase of 10% (8% on a constant currency basis, which strips out exchange-rate swings). Sleep and Breathing Health grew 10%, driven by demand and unit sales across the sleep health portfolio, partly offset by lower unit sales of life support devices.
  • Residential Care Software revenue rose 5% to $676 million. Growth in MEDIFOX DAN, Home and Hospice, and Home Medical Equipment was partly offset by weakness in Senior Living and Long-Term Care.
  • Gross margin improved to 61.1% from 59.4%, helped by procurement, manufacturing and logistics efficiencies. A field safety notification on Astral devices, to replace a component, partly offset the gain.
  • Net income was $1,523 million, or $10.43 per diluted share, versus $1,401 million, or $9.51. The effective tax rate rose to 20.6% from 16.5%, mainly because of the Pillar Two global minimum tax.
  • Operating cash flow was $1,806 million. The company repurchased $700 million of stock and paid $350 million in dividends. It also recorded $22 million of restructuring charges for severance.

Risks specific to this company

  • Competition: The filing names GLP-1 weight-loss drugs as a possible threat to sleep apnea demand. It also says Philips, which operates under a consent decree after its recall, could return and reduce demand for ResMed products.
  • Supply: Some component suppliers are single-source. Chinese export controls on rare earth magnets could raise costs or limit supply. Substantially all products are made outside the U.S., with facilities in Sydney and Singapore exposed to natural disasters.
  • Reimbursement: U.S. customers depend on Medicare and insurer payments, and cuts can flow back to ResMed. The newly acquired Noctrix restless legs device has no national or local coverage determination, so claims could be denied. A proposed VA change to sleep apnea disability ratings is unresolved.
  • New healthcare oversight: VirtuOx and Noctrix bill Medicare directly, which brings fraud and abuse and privacy rules ResMed historically did not face. VirtuOx is under a five-year corporate integrity agreement (a government compliance monitoring deal) through 2027, after a $3 million settlement.
  • Tax: Pillar Two had a material impact on tax expense and cash flows and may affect fiscal year 2027. The Australian Taxation Office is auditing the 2018 tax year.
  • Debt: Total outstanding debt was $660 million at June 30, 2026. The filing says debt service takes a share of operating cash flow.

What management is watching

  • Portfolio changes: The MatrixCare sale for $490 million in cash is expected to close in the first quarter of fiscal year 2027. MatrixCare represented approximately $220 million of revenue in fiscal 2026. Management is also integrating Noctrix, acquired in June 2026.
  • Spending: R&D was $378 million, or 6.7% of net revenues, with a focus on new products such as AirSense 11. SG&A also rose on employee costs, acquisitions, and marketing and technology investment.
  • Non-GAAP measures: Management points to non-GAAP figures, which exclude items like acquired-intangible amortization and field safety costs. Non-GAAP operating margin was 36.1% and non-GAAP diluted earnings per share was $11.17.
  • Cash and capital return: The board declared a $0.66 per share dividend on August 6, 2026. The filing stresses that dividends and buybacks are at board discretion. Management expects to repatriate foreign earnings to the U.S. during fiscal year 2027.
  • Debt: The $250 million 3.24% senior notes matured and were repaid on July 10, 2026. The revolving and term credit agreements end on Jun 29, 2027.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

ResMed grew net revenue 6% to $1,415 million for the three months ended September 30, 2026, led by its sleep and breathing health business. Diluted earnings per share was $2.92 versus $2.37 a year earlier, helped by a $62 million gain from selling the MatrixCare software business on September 1, 2026. The company also put a large amount of cash into share repurchases.

How the business did

  • Revenue: Sleep and Breathing Health revenue was $1,260 million, up 8%. Devices were $720 million (up 6%) and masks and other were $540 million (up 10%). Management credits demand and unit sales, plus device fleet renewals in France, partly offset by lower life support device sales as the Astral device is discontinued.
  • Software segment: Residential Care Software revenue fell 7% to $155 million, mainly because MatrixCare was sold. The MEDIFOX DAN and Brightree businesses grew.
  • Profit: Gross margin was 61.5% versus 61.2%. Research and development rose 15% to $103 million and selling, general and administrative costs rose 12% to $315 million. Net income was $418 million versus $349 million. Non-GAAP diluted earnings per share, which strips out items such as the sale gain, was $2.91 versus $2.55.
  • Unusual items: Restructuring and business transformation costs were $20 million in selling, general and administrative expenses, and $10 million of acquisition and divestment-related expenses came mostly from the MatrixCare sale.
  • Cash and capital return: Operating cash flow was $422 million versus $457 million, with higher inventory a factor. The company repurchased 3.6 million shares at a cost of $855 million and entered a $450 million accelerated share repurchase (ASR), where shares are delivered up front and the final count is settled later. It also paid dividends of $0.66 per share totaling $95 million and repaid $250 million of senior notes. Cash fell to $1.0 billion from $1.5 billion at June 30, 2026.

What management is watching

  • Costs: The company says inflationary pressure on manufacturing inputs, especially electronic components, should continue through the remainder of fiscal year 2027. Expanding its supply chain to new sites may also make gross margin fluctuate.
  • Spending: Research and development was 7.3% of net revenues. The company is funding growth and transformation initiatives, including supply chain process and systems work, and cites expenses from the Noctrix acquisition.
  • Capital return and liquidity: The ASR is expected to settle no later than December 29, 2026. A $0.66 per share dividend was declared on October 29, 2026, payable December 17, 2026. The company reports $2,511 million in cash and available revolving credit, and says its liquidity is sufficient for the next 12 months and beyond. The revolving and term credit agreements end on June 29, 2027.
  • Measures cited: Management points to constant currency growth, which removes exchange rate effects, and core constant currency growth, which also removes acquisitions and divestitures. Core constant currency revenue growth was 7%. It also uses non-GAAP gross margin, operating income, net income and earnings per share.

Follow RMD in Kortex

The Kortex app shows RMD's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.